Rituximab in juvenile myasthenia gravis-an international cohort study and literature review.

Ramdas, Sithara; Della Marina, Adela; Ryan, Monique M; McWilliam, Kenneth; Klein, Andrea; Jacquier, David; Alabaf, Setareh; Childs, Anne-Marie; Parasuraman, Deepak; Beeson, David; Palace, Jacqueline; Jungbluth, Heinz (2022). Rituximab in juvenile myasthenia gravis-an international cohort study and literature review. European journal of paediatric neurology, 40, pp. 5-10. Elsevier 10.1016/j.ejpn.2022.06.009

[img] Text
1-s2.0-S1090379822000964-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

Juvenile myasthenia gravis (JMG) is a rare, antibody-mediated disorder of the neuromuscular junction. Treatment strategies in JMG are largely informed by adult MG treatments as the pathophysiology is similar. Rituximab is increasingly considered as a treatment option in refractory JMG but has not yet been systematically investigated in this patient group We conducted a retrospective study from five international centres with expertise in paediatric myasthenia. 10 JMG patients treated with rituximab were identified. Following rituximab treatment all patients had a reduction in JMG-related hospital admissions. At 24 month follow up, 6 patients (60%) had achieved complete stable remission or pharmacological remission and 7 patients were able to reduce immunomodulatory treatment(s). The main side-effect was infusion-related reactions (30%) which resolved in all patients with symptomatic treatment. We compared our cohort to previously reported JMG cases treated with rituximab and noted similar response rates but a slightly higher side-effect profile. Rituximab is a safe and effective treatment option in moderate to severe JMG and most patients have an improvement in MG symptoms post treatment.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Neuropaediatrics

UniBE Contributor:

Klein, Andrea Katharina

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1090-3798

Publisher:

Elsevier

Language:

English

Submitter:

Anette van Dorland

Date Deposited:

18 Jul 2022 08:28

Last Modified:

05 Dec 2022 16:21

Publisher DOI:

10.1016/j.ejpn.2022.06.009

PubMed ID:

35835035

Uncontrolled Keywords:

Juvenile myasthenia gravis Myasthenia gravis Paediatric Rituximab

BORIS DOI:

10.48350/171324

URI:

https://boris.unibe.ch/id/eprint/171324

Actions (login required)

Edit item Edit item
Provide Feedback